AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tumor necrosis factor receptor superfamily member 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P43489

UPID:

TNR4_HUMAN

Alternative names:

ACT35 antigen; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor

Alternative UPACC:

P43489; Q13663; Q2M312; Q5T7M0

Background:

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40L receptor, ACT35 antigen, and TAX transcriptionally-activated glycoprotein 1 receptor, plays a pivotal role in immune system regulation. It serves as a receptor for TNFSF4/OX40L/GP34, enhancing long-term T-cell immunity and acting as a receptor for human herpesvirus 6B/HHV-6B.

Therapeutic significance:

TNFRSF4's involvement in Immunodeficiency 16, a condition marked by poor T-cell recall immune responses and susceptibility to classic Kaposi sarcoma, underscores its therapeutic potential. Targeting TNFRSF4 could lead to innovative treatments for this immunodeficiency and other T-cell related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.